{"title":"BMS买下了Orum的抗癌药物","authors":"None Laura Howes","doi":"10.1021/cen-10137-buscon14","DOIUrl":null,"url":null,"abstract":"Bristol Myers Squibb has purchased Orum Therapeutics’ protein degrader for treating acute myeloid leukemia or high-risk myelodyplastic syndromes. For an up-front payment of $100 million, BMS gets ORM-6151, a molecular-glue drug that is coupled to an antibody. The antibody helps the drug be delivered to cancer cells. There, the glue portion of ORM-6151 is released and marks the target protein GSPT1 for degradation, which ultimately kills the cancer cell.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"28 12","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BMS buys Orum’s cancer drug\",\"authors\":\"None Laura Howes\",\"doi\":\"10.1021/cen-10137-buscon14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bristol Myers Squibb has purchased Orum Therapeutics’ protein degrader for treating acute myeloid leukemia or high-risk myelodyplastic syndromes. For an up-front payment of $100 million, BMS gets ORM-6151, a molecular-glue drug that is coupled to an antibody. The antibody helps the drug be delivered to cancer cells. There, the glue portion of ORM-6151 is released and marks the target protein GSPT1 for degradation, which ultimately kills the cancer cell.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"28 12\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10137-buscon14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10137-buscon14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bristol Myers Squibb has purchased Orum Therapeutics’ protein degrader for treating acute myeloid leukemia or high-risk myelodyplastic syndromes. For an up-front payment of $100 million, BMS gets ORM-6151, a molecular-glue drug that is coupled to an antibody. The antibody helps the drug be delivered to cancer cells. There, the glue portion of ORM-6151 is released and marks the target protein GSPT1 for degradation, which ultimately kills the cancer cell.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
